Objectives: Evidence suggests use of proton pump inhibitors (PPIs) and H2 blockers may provoke disease flares in individuals with established inflammatory bowel disease (IBD); however, there are no studies investigating the relationship of these medications with risk of developing pediatric IBD. The hypothesis was that use of acid suppression therapy in children might be associated with development of pediatric IBD.
Methods: This was a nested case-control study of 285 Kaiser Permanente Northern California members, age ≤21 years diagnosed with IBD from 1996 to 2016. Four controls without IBD were matched to each case on age, race, and membership status at the case's index date. Disease risk scores (DRS) were computed for each subject. Odds ratios and 95% confidence intervals were calculated by using conditional logistic regression models adjusted for DRS.
Results: The children's mean age was 15.1 ± 2.6 years and 49.5% were female. Six cases (n = 3 Crohn's disease [CD], n = 3 ulcerative colitis [UC]) and 6 controls were prescribed PPIs and 10 cases (n = 7 CD, n = 3 UC) and 28 controls were prescribed H2 blockers. The OR for the association of at least 1 PPI or H2 blocker prescription with subsequent IBD was 3.6 (95% CI, 1.1-11.7) for PPIs and 1.6 (95% CI, 0.7-3.7) for H2 blockers.
Conclusions: Early-life PPI use appears to be associated with subsequent IBD risk. These findings have implications for clinical treatment of children with gastrointestinal symptoms and warrant further investigation in a larger cohort.
Keywords: child; epidemiology; inflammatory bowel disease; pharmacoepidemiology.
Copyright Published by the Pediatric Pharmacy Association. All rights reserved. For permissions, email: email@example.com 2019.
Conflict of interest statement
Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. The authors had full access to all the data and take responsibility for the integrity and accuracy of the data analysis.
Gastric Acid Suppression Is Associated With an Increased Risk of Adverse Outcomes in Inflammatory Bowel DiseaseR Shah et al. Digestion 95 (3), 188-193. PMID 28288458.H2RAs and PPIs were associated with a modestly increased risk of IBD-related hospitalization or surgery.
Increased Risk of Pneumonia Among Patients With Inflammatory Bowel DiseaseMD Long et al. Am J Gastroenterol 108 (2), 240-8. PMID 23295276.Patients with IBD are at increased risk for pneumonia. Medications such as corticosteroids and narcotics are particularly associated with pneumonia in this population. An …
Drugs That Inhibit Gastric Acid Secretion May Alter the Course of Inflammatory Bowel DiseaseP Juillerat et al. Aliment Pharmacol Ther 36 (3), 239-47. PMID 22670722.Initiation of PPIs or H2Ra may be associated with short-term changes in the course of IBD. Although confounding by indication was adjusted using propensity score matching …
Antibiotics Associated With Increased Risk of New-Onset Crohn's Disease but Not Ulcerative Colitis: A Meta-AnalysisR Ungaro et al. Am J Gastroenterol 109 (11), 1728-38. PMID 25223575. - ReviewExposure to antibiotics appears to increase the odds of being newly diagnosed with CD but not UC. This risk is most marked in children diagnosed with CD.
Helminth Therapy (Worms) for Induction of Remission in Inflammatory Bowel DiseaseSK Garg et al. Cochrane Database Syst Rev (1), CD009400. PMID 24442917. - ReviewCurrently, there is insufficient evidence to allow any firm conclusions regarding the efficacy and safety of helminths used to treat patients with IBD. The evidence for o …